Q May Wang

Title: Q May Wang: Innovator in Peptidomimetic Protease Inhibitors

Introduction

Q May Wang is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of peptidomimetic compounds. With a total of 7 patents to her name, her work focuses on innovative solutions for treating hepatitis C infections.

Latest Patents

One of her latest patents involves peptidomimetic protease inhibitors. This invention relates to compounds that serve as protease inhibitors, specifically targeting serine proteases and, more importantly, the hepatitis C NS3 protease. The patent details the preparation of these compounds, including novel stereoselective processes. Additionally, it encompasses pharmaceutical compositions and methods for using these compounds to inhibit HCV protease or treat patients suffering from HCV infections. The invention also includes pharmaceutical combinations with interferons exhibiting anti-HCV activity and methods for treating or preventing HCV infections in patients.

Career Highlights

Throughout her career, Q May Wang has worked with notable companies such as Eli Lilly and Company and Vertex Pharmaceuticals, Inc. Her experience in these organizations has contributed to her expertise in the pharmaceutical industry and her innovative research.

Collaborations

Some of her notable coworkers include Robert Edward Babine and Ivan Collado. Their collaboration has likely fostered a productive environment for innovation and research.

Conclusion

Q May Wang is a distinguished inventor whose work in peptidomimetic protease inhibitors has the potential to significantly impact the treatment of hepatitis C. Her contributions to the pharmaceutical field highlight the importance of innovation in addressing critical health challenges.